Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sonpiretigene isteparvovec - Nanoscope Therapeutics

Next Previous
Drug Profile

Sonpiretigene isteparvovec - Nanoscope Therapeutics

Alternative Names: MCO-010; vMCO 1; vMCO-010

Latest Information Update: 14 Nov 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nanoscope Therapeutics
  • Class Eye disorder therapies; Gene therapies
  • Mechanism of Action Eye protein replacements; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Stargardt disease; Retinitis pigmentosa
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Retinitis pigmentosa
  • Phase II Stargardt disease
  • No development reported Dry age-related macular degeneration

Most Recent Events

  • 04 Nov 2025 Efficacy and adverse events data from a phase I/IIa trial in Retinitis pigmentosa released by Nanoscope thearpeutics
  • 02 Sep 2025 Sonpiretigene isteparvovec - Nanoscope Therapeutics receives Regenerative Medicine Advanced Therapy (RMAT) status for Stargardt disease in USA
  • 26 Aug 2025 MCO 010 receives orphan designations for non-syndromic dystrophy, syndromic rod-dominant dystrophy, cone-dominant dystrophy and macular dystrophy

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top